Introduction
The mouse epidermal JB6 genetic variants, namely transformation-resistant (PÀ), transformation-susceptible (P+), and transformed (Tx) cells, are a useful tool for studying tumor promotion and progression at a molecular level. Exposure of P+ cells to tumor promoters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) or epidermal growth factor (EGF) produces transformed (Tx) cells that are able to form anchorageindependent colonies in soft agar (Colburn et al., 1979) and tumors when injected into mice (Colburn, 1980; Takahashi et al., 1986) . PÀ variants are resistant to tumor promoter-induced anchorage-independent transformation. Several events have been identified as required events in promoter-induced transformation in JB6 cells, including activation of transcription factor AP-1 and NF-kB, elevation of ERK1/2, and activation of ornithine decarboxylase (ODC) (reviewed in Hsu et al., 2000) . Less is known of the molecular events critical to the maintenance of tumor phenotype in Tx cells. Comparison of basal AP-1 transcriptional activity in JB6 PÀ, P+, and Tx cells revealed that Tx cells have the highest AP-1 activity (Dong et al., 1995b) ; elevation of AP-1 activity with tumor progression is often seen in human cancer models as well (Li et al., 1998; Liu et al., 2002) . Transformed RT101 (Tx) cells treated with retinoic acid, glucocorticoid, and/or forskolin are suppressed for anchorage-independent colony formation with concomitant reduction of AP-1 transcriptional activity (Dong et al., 1995a) , suggesting that maintenance of elevated AP-1 activity is critical for tumorigenic phenotype.
The expression of mouse Pdcd4 gene is upregulated or downregulated in response to apoptosis inducers and COX2 inhibitor treatments (Onishi and Kizaki, 1996; Zhang and DuBois et al., 2001; Chauhan et al., 2002) . Pdcd4 expression is downregulated by interleukin-2 and topoisomerase inhibitor treatments (Shibahara et al., 1995; Azzoni et al., 1998) . No causal relation to these treatments was, however, established. A differential display of mRNA in P+ and PÀ cells identified Pdcd4 as preferentially expressed in JB6 PÀ cells (Cmarik et al., 1999) . Overexpression of sense pdcd4 in P+ cells produced a transformation-resistant phenotype, indicating that Pdcd4 is a suppressor of tumor promoterinduced transformation (Yang et al., 2001) . Pdcd4 inhibits AP-1 activation in P+ cells in a concentration-dependent manner, but does not inhibit Serum response element (SRE) or ODC activation, suggesting that Pdcd4 may owe its transformation-inhibiting activity to suppression of AP-1-dependent transcriptional activity (Yang et al., 2001) . Targeting a particular activity may effectively inhibit cancer progression at early stages but may not necessarily suppress tumor phenotype or late-stage tumor progression. For example, targeting matrix metalloproteinases can delay or prevent early-stage progression but have an enhancing effect on late-stage tumor progression (Coussens et al., 2002) . Thus, whether Pdcd4 is able to suppress not only induction of tumor phenotype but also expression or maintenance of tumor phenotype needs to be ascertained.
In the present study, we have demonstrated that overexpression of Pdcd4 is sufficient to inhibit anchorage-independent colony formation and colony growth in JB6 Tx cells. To explore the possible mechanism by which Pdcd4 suppresses transformed cell phenotype, we overexpressed Pdcd4 in RT101 cells and asked whether Pdcd4 inhibited AP-1 transactivation. Pdcd4 inhibits AP-1-dependent transcription in a concentration-dependent manner. The inhibition of AP-1-dependent transcription appears to involve inhibition of the transactivation of c-Jun and possibly c-Fos.
Results

Pdcd4 protein expression is downregulated in RT101 cells
Pdcd4 expression is downregulated in JB6 P+ cells at both the mRNA and the protein levels when compared to PÀ cells (Cmarik et al., 1999; Yang et al., 2001) . However, it is not known whether downregulation of Pdcd4 expression also occurs in the transformed JB6 Tx cells. To address this question, we performed a Western immunoblot using Cl 30.7b (PÀ), Cl 41 (P+), and RT101 (Tx) cell lysates (Figure 1 ). RT101 cells are tumorigenic cells that were obtained when the P+ Cl 41 cells were treated repeatedly with tumor promoter (Colburn et al., 1981) . The expression of endogenous Pdcd4 was about 5-7-fold lower in the P+ cells than in the PÀ cells, in agreement with previous observations (Cmarik et al., 1999; Yang et al., 2001) . The level of Pdcd4 in the RT101 cells is undetectable, indicating that the conversion of P+ to tumorigenic cells (Tx) is accompanied by a further reduction in Pdcd4 expression. A faint band is seen around 53 kDa in size in the RT101 cell lysates but not in 30.7b or Cl 41 cell lysates (indicated as an arrowhead in Figure 1 ). This band was competed by pdcd4 peptide (data not shown). The size of this band is identical to that of recombinant Pdcd4 protein purified from baculovirus-infected insect cells (data not shown), suggesting that the 64 kDa Pdcd4 protein has been post-translationally modified to a slower migrating form. Several potential consensus sites for phosphorylation, glycosylation, and myristoylation are identified in the Pdcd4 protein sequence. The functions of post-translational modification of Pdcd4 protein are unknown.
Pdcd4 inhibits anchorage-independent growth of Tx cells
Previously we demonstrated that downregulation of endogenous Pdcd4 expression by antisense pdcd4 converted transformation-resistant PÀ cells to the susceptible P+ phenotype (Cmarik et al., 1999) . Overexpression of Pdcd4 in P+ cells suppressed TPAinduced neoplastic transformation (Yang et al., 2001) . However, it is unknown whether Pdcd4 is able to reverse or suppress the tumor phenotype of transformed JB6 RT101 cells. To address this question, we performed a stable transfection of pdcd4 expression plasmid, pcDNA-pdcd4, into RT101 cells. The pooled RT101 cells were selected in G418 for 14 days. As shown in Figure 2 , Pdcd4 expression was restored in the stably transfected 101/pdcd4-1 and 101/pdcd4-2 cells (lanes 3 and 4). Transfectant 101/pdcd4-2 expressed about 3-4-fold higher Pdcd4 than transfectant 101/pdcd4-1. The levels of Pdcd4 in the vector control cells (lanes 1 and 2) remained undetectable. These pooled-clone transfectants were subsequently analysed for anchorage-independent colony formation. Transfectants 101/pdcd4-1 and 101/pdcd4-2 formed approximately 1100 colonies per 10 4 cells ( showed approximately 1800-1900 colonies per 10 4 cells. Although overexpression of Pdcd4 leads to about 40% reduction in anchorage-independent colony number, the size of colonies overexpressing pdcd4 was significantly smaller than in vector control cells (Figure 3 ). This result suggests that overexpression of pdcd4 in RT101 cells may slow anchorage-independent growth as well as reduce colony number. The magnitude of suppression of RT101 tumor cell phenotype is not proportional to the levels of Pdcd4 protein in these stably transfected cells; 101/pdcd4-2 transfectants have a higher level of Pdcd4 protein ( Figure 2 ) but a similar degree of suppression of tumor cell phenotype as 101/pdcd4-1 (Figure 3a and b) . This finding suggests that suppression of tumor phenotype occurs when Pdcd4 expression exceeds a concentration threshold.
Pdcd4 inhibits AP-1 but not SRE-dependent transcription
RT101 cells showed 3-4-fold higher constitutive AP-1 transactivation than P+ cells (Dong et al., 1995b) . Inhibition of AP-1 transcriptional activation by treatment of RT101 cells with retinoic acid, forskolin, or combinations is accompanied by blocking anchorageindependent colony formation (Dong et al., 1995a) , suggesting that inhibition of AP-1 activation may reverse or suppress RT101 tumor phenotype. To determine whether Pdcd4 protein inhibits the elevated AP-1 transcriptional activation seen in Tx RT101 cells, a pdcd4 expression plasmid (pcDNA-pdcd4) was cotransfected with 4 Â AP-1 reporter plasmid (4 Â AP-1 Luc) into RT101 cells. As shown in Figure 4 , transient cotransfection of pcDNA-pdcd4 and 4 Â AP-1-Luc inhibited AP-1-dependent transactivation in a concentration-dependent manner. AP-1-dependent transactivation is approximately 50% inhibited at a 6 : 1 ratio of pcDNA-pdcd4 to 4 Â AP-1 reporter. Previously, we found that Pdcd4 inhibited 50% of TPA-induced AP-1-dependent transactivation at a 3 : 1 ratio of pcDNApdcd4 to reporter in P+ cells (Yang et al., 2001) . The higher ratio of pcDNA-pdcd4 to reporter needed in the RT101 cells to obtain the same level (50%) of AP-1 inhibition may reflect the higher basal level of AP-1 activity in RT101 cells (Dong et al., 1995b) . This 50% inhibition of AP-1-dependent transactivation by Pdcd4 protein was concomitant with suppression of TPAinduced neoplastic transformation of JB6 P+ cells (Yang et al., 2001 ) and with suppression of tumor phenotype in human keratinocytes (Li et al., 1998, Figure 3 Suppression of anchorage-independent phenotype by Pdcd4 expression in RT 101 cells. Transfectants 101/vector-1, 101/ vector-2, 101/pdcd4-1, and 101/pdcd4-2 were subjected to an anchorage-independent growth assay as described in Materials and methods. After 14 days, colonies of greater than eight cells were counted by an automated image analysis system with Image Pro-Plus software (Media Cybernetics) (Hsu et al., 2001) . These experiments were repeated twice with duplicates and representative pictures are shown . These findings suggest that this magnitude of inhibition of AP-1-dependent transactivation is sufficient to suppress transformation or reverse tumorigenic phenotype.
In contrast, cotransfection of pcDNA-pdcd4 expression plasmid and SRE-luciferase reporter (SRE-Luc) produced no significant decrease in SRE activation (Figure 4b ), indicating that Pdcd4 protein specifically inhibits AP-1-dependent transcriptional activation rather than inhibiting transcription generally.
Pdcd4 does not inhibit the synthesis of AP-1 proteins
The AP-1 complex that binds to DNA consists of either a Jun/Jun homodimer or a Jun/Fos heterodimer. Inhibition of AP-1-dependent transcription by Pdcd4 may be through (i) sequestering Jun or Fos proteins, (ii) inhibiting Jun or Fos protein synthesis, or (iii) inhibiting activation of Jun or Fos proteins. Based on the observations in the JB6 P+ cells that ectopic introduction of AP-1 proteins does not relieve inhibition of AP-1-dependent transcription by Pdcd4 (Yang et al., 2001) and that GST-Pdcd4 does not pull down Fra-1 and cFos from TPA-treated P+ cell lysates (unpublished data), it is not likely that the protein-protein interaction between Pdcd4 and AP-1 proteins occurs in the JB6 genetic variant RT101 cells. In addition, a yeast twohybrid analysis does not identify any AP-1 proteins as Pdcd4 binding partners (Yang et al., 2003) . Thus, the sequestration mechanism is not likely to occur in the RT 101 cells. To test whether overexpression of Pdcd4 inhibits the synthesis of Jun or Fos proteins, a Western blot was performed using cell lysates that were prepared from RT101 cells overexpressing Pdcd4. The expression of Pdcd4 is about 4-5-fold higher in the cell lysates transfected with pcDNA-pdcd4 than in the cell lysates transfected with control vector ( Figure 5 ). The expression of AP-1 proteins (c-Jun, JunB, JunD, c-Fos, Fra-1, Fra-2, and FosB) did not show a significant difference between the cells overexpressing Pdcd4 and vector control. This finding indicates that, within the limits of detection, Pdcd4 does not inhibit the synthesis of Jun or Fos proteins.
Pdcd4 specifically inhibits c-Jun and c-Fos transactivation
To determine whether the activation of Jun or Fos proteins was inhibited by Pdcd4 protein, we performed a Gal4 assay. Transactivation domains of Jun or Fos proteins DNA were fused to the yeast Gal4 DNAbinding domain and cotransfected with Gal4-luciferase reporter and pcDNA-pdcd4 (or pcDNA) plasmid. The luciferase reporter becomes activated when a Gal4-Jun or -Fos activation domain fusion protein binds to the Gal4-luciferase reporter, but only when the Jun or Fos activation domain has become transactivated. Any luciferase activity change reflects enhancement or reduction of the Jun or Fos protein transactivation. Since FosB does not become activated in JB6 cells (Kazumi and Colburn, 2002) , we only tested c-Jun, JunB, JunD, c-Fos, Fra-1, and Fra-2 activation in RT101 cells. As shown in Figure 6a , the Gal4-fused cJun, JunB, JunD, c-Fos, and Fra-1 each stimulated luciferase expression from five to 30-fold compared to empty vector (FA), indicating that these Gal4-Jun or Gal4-Fos protein activation domain fusion proteins were expressed and functioned in RT101 cells. The Gal4-Fra-2 showed a level of luciferase expression similar to that of empty vector, indicating that Gal4-Fra-2 was not activated in RT101 cells as seen previously with P+ Cl 41 cells (Young et al., 2002) .
Pdcd4 specifically inhibited c-Jun and c-Fos activation but not that of Fra-1, JunB, or JunD (Figure 6b To test whether the components of the AP-1 complex were altered when Pdcd4 was overexpressed in RT101 cells, the nuclear extracts from cells that were transiently transfected with pcDNA-pdcd4 (or pcDNA) were prepared. As shown in Figure 7c , nuclear extracts of Pdcd4 overexpressed and vector control cells showed essentially identical supershifted bands, blocked shifts, or lack thereof when c-Jun, c-Fos, Fra-1 or JunD antibodies were added to the AP-1-DNA complex. This result indicates that Pdcd4 expression does not detectably alter the components of the AP-1 complex in RT101 cells.
Discussion
The present study demonstrates that the level of Pdcd4 protein expression is downregulated in transformed JB6 RT101 cells. Elevation of Pdcd4 expression is sufficient to suppress the tumor cell phenotype. Recently, a yeast two-hybrid analysis has identified translation initiation factor 4A (eIF4A) as a major binding partner of Pdcd4 (Yang et al., 2003) . Binding of Pdcd4 to eIF4A inhibits eIF4A's helicase activity and inhibits translation (Yang et al., 2003) . Translation initiation factor eIF4A is an RNA helicase whose function in translation is thought to involve unwinding mRNA secondary structure in the 5 0 -untranslated region (Rogers et al., 2002) . Inhibition of the eIF4A helicase activity by dominant negative eIF4A mutants results in inhibition of translation (Pause et al., 1994) .
The more stable the secondary structure within the 5 0 end of mRNA, the greater the requirement for eIF4A activity in translation (Svitkin et al., 2001) . Thus, Pdcd4 may inhibit the translation of mRNAs having stable 5 0 -untranslated regions that directly or indirectly activate c-Jun and c-Fos activation domains. Identification of Pdcd4 target mRNAs is important.
AP-1 is a complex of transcription factors comprised of homodimers of Jun (c-Jun, JunB, and JunD) family proteins or heterodimers of Jun and Fos (c-Fos, FosB, Fra-1, and Fra-2) family proteins, belonging to the bZIP family. The Jun/Jun or Jun/Fos dimers bind with higher affinity to the TPA response element, TGA(G/C)TCA, and with lower affinity to the cAMP response element, TGACGTCA (Chinenov and Kerppola, 2001) homodimer, c-Jun/JunB, c-Jun/c-Fos, or an other c-Jun/ Fos family heterodimer, but the AP-1 complex apparently does not contain JunD or Fra-1 proteins. Overexpression of Pdcd4 in RT101 cells does not detectably alter Jun/Fos supershift bands or blocked shifts of AP-1-DNA complexes, suggesting that other molecules may be limiting for activation of the AP-1 complex. Several proteins have been reported to interact with the AP-1 complex including CBP/p300, SMAD-3, and retinoblastoma protein (Chinenov and Kerppola, 2001 ). These proteins may enhance or repress the AP-1 activity but may not be seen in the EMSA. It is noteworthy that this result does not exclude the possibility that Pdcd4 modestly inhibits AP-1-DNA complex formation. Since the efficiency of transient transfection is about 30-40%, EMSA may not be sufficiently sensitive to detect a modest decrease in AP-1-DNA complex formation. AP-1-dependent transcription has been shown to play a critical role in cell proliferation, transformation, and cell invasion (Ozanne et al., 2000; Karin, 2001, 2002) . Overexpression of human c-jun mRNA transforms immortalized fibroblast rat 1a cells and renders cells tumorigenic when injected into nude mice (Schutte et al., 1989a) . c-Jun overexpression also greatly enhances the tumorigenic, invasive and hormone-resistant phenotype of the breast cancer cell line MCF7 (Smith et al., 1999) . Overexpression of c-Fos alone is not sufficient to transform but c-Fos is able to stimulate the transforming capacity when it is coexpressed with c-Jun (Schutte et al., 1989b) . In addition, overexpression of dominant negative c-jun in transformed cells resulted in decreased AP-1 activity (of all AP-1 dimers) and reversion to the normal phenotype (Domann et al., 1994; Rapp et al., 1994; Suzuki et al., 1994) . Therefore, elevated AP-1 activity is essential for maintenance of transformed phenotype. The finding that Pdcd4 inhibits both AP-1 transactivation and anchorage-independent colony formation/growth in RT101 cells suggests that inhibition of AP-1 activity by Pdcd4 suppresses the tumor cell phenotype. This argument is in agreement with previous observations that AP-1 inhibitors, retinoic acid and forskolin, suppressed the transformed phenotype in RT101 cells (Dong et al., 1995a) . It is not known whether a certain threshold of AP-1 activity is required for maintaining the tumor cell phenotype. Previous results (Dong et al., 1995a) and the current study suggest that 50% inhibition of AP-1 activity is sufficient to at least partially suppress the JB6 Tx cell phenotype. This magnitude of AP-1 inhibition was also observed in human keratinocytes when expression of tetracyclineregulated dominant negative c-jun TAM67 inhibited AP-1 transactivation by approximately 50% and suppressed tumor phenotype by 90% (Li et al., 2000) . Inhibition of AP-1 activity by Pdcd4 required a higher ratio of pcDNA-pdcd4 plasmid to 4 Â AP-1-Luc reporter in Tx cells than that in P+ cells. This result may reflect the higher AP-1 activity in RT101 cells (Dong et al., 1995b) .
Previously, we demonstrated that elevating Pdcd4 expression inhibits TPA-induced neoplastic transformation in JB6 P+ cells, possibly through inhibiting Ap-1-dependent transcriptional activation (Yang et al., 2001) . A gel mobility shift showed that TPA-activated AP-1 complex contains significantly more Fra-1 protein in P+ cells than in PÀ cells (Young et al., 2002) . Mutations that inactivated Fra-1 protein phosphorylation resulted in a decrease of TPA-induced Fra-1 activation and Ap-1-dependent transcriptional activity (Young et al., 2002) . In addition, JunD protein is preferentially expressed in P+ cells and its DNAbinding ability is significantly higher in P+ cells than in PÀ cells (Bernstein and Walker, 1999) . These observations indicate that Fra-1 and JunD are critical components in the TPA-activated AP-1 complex in P+ cells. The components of the AP-1 complex in RT101 Tx cells are apparently different from those in P+ cells, with cJun distinguishing the Tx cells.
The finding that Pdcd4 inhibits c-Jun and c-Fos transactivation but not that of JunB, JunD, or Fra-1 (Figure 6 ) may contribute to the significantly smaller anchorage-independent colony size of stable Pdcd4 transfectants (101/pdcd4-1 and 101/pdcd4-2) relative to vector controls (Figure 3) . Proteins c-Jun and/or c-Fos have been shown to be required for proliferation and cell cycle progression (Holt et al., 1986; Nishikura and Murray, 1987; Kovary and Bravo, 1991; Angel et al., 2001) . Fibroblasts from c-jun knockout mouse embryos are defective in proliferation, and even after immortalization, these cells still proliferate more slowly than wild-type cells (Schreiber et al., 1999) . Moreover, overexpression of c-jun cDNA in P+ cells produces a transformed phenotype (Watts et al., 1995) , indicating that elevation of c-Jun expression may be sufficient to maintain the transformed phenotype in the Tx cells. Inhibition of c-Jun activation (Figure 6b ) may contribute to suppressing the transformed phenotype by slowing cell growth resulting in smaller colony size.
In conclusion, these findings establish that Pdcd4 not only suppresses TPA-induced transformation (Yang et al., 2001 ) but also suppresses expression of the transformed phenotype. The mechanism of suppressing tumor phenotype appears to involve inhibiting AP-1 activation by inhibiting activation, not synthesis, of cJun and c-Fos. Thus, Pdcd4 may have potential value as a molecular target for cancer therapy.
Materials and methods
Cell culture
The JB6 RT101 cells were obtained from ATCC (CRL-2002) . Cells were grown in Eagle's minimal essential medium (EMEM) containing 4% fetal bovine serum, 2 mm l-glutamine and 25 mg/ml gentamicin at 371C in a humidified atmosphere of 5% CO 2 in air.
Plasmids and reagents pcDNA3.1+, pcDNA-pdcd4, 4 Â AP-1 luciferase reporter plasmid, and serum response element luciferase reporter plasmid were as previously described (Yang et al., 2001) . Gal4 fusion AP-1 proteins were described in Young et al. (2002) . EMEM was purchased from BioWhittaker. FuGene 6 transfection reagent and protease inhibitor tablet were obtained from Roche Molecular Biochemicals. The luciferase assay kit was purchased from Promega.
Transfection and luciferase assay JB6 RT101 cells (1 Â 10 4 cells/well in a 24-well plate) were transfected with a total of 1.2 mg of DNA (as described in the figure legends) using 2 ml of Fugene 6 reagent. After incubation at 371C for 4 h, 1 ml of fresh EMEM with 4% FBS was then added into each well and incubated for an additional 16-18 h. Cells were serum starved in EMEM with 0.2% FBS for 24 h to lower the AP-1 background. EMEM with 0.2% FBS was then replaced by 1 ml of EMEM with 4% FBS. After 6 h, cells were lysed and assayed for luciferase activity as previously described (Yang et al., 2001 ).
Anchorage-independent growth assay
Ten thousand cells were suspended in 1.5 ml of 0.33% EMEM agar with 10% FBS and layered over 7 ml of 0.5% EMEM agar with 10% FBS in a 60-mm tissue culture dish. The cells were cultured at 371C, 5% CO 2 for 14 days and stained with 1% neutral red. Colonies greater than eight cells were counted by an automated image analysis system with Image Pro-Plus software (Media Cybernetics) (Hsu et al., 2001 ).
Preparation of cell lysates and Western blot
RT101 cells were washed with PBS twice and lysed in lysis buffer (25 mm Tris (pH 7.5), 2% SDS, 1 Â protease inhibitors mixture (Roche Biochemicals)). Lysed samples were sheared by passage through a 22-gauge needle. Protein concentration was determined by the BCA protein assay kit (Pierce). Western blot was performed as previously described (Yang et al., 2001) . Briefly, aliquots containing 10 mg protein were separated on 10% NuPage Bis-Tris polyacrylamide gel (Invitrogen) and transferred to nitrocellulose membranes. The protein-bound membrane was incubated with Pdcd4 specific antibody (Yang et al., 2001) (1 : 10 000 dilution) followed by horseradish peroxidase-linked anti-rabbit IgG (1 : 10 000 dilution) (Amersham). The Pdcd4 was visualized by chemiluminescence (ECL, Amersham).
Electrophoretic mobility shift assay (EMSA)
The RT101 nuclear extracts were prepared by the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Pierce) and the protein concentration was determined by the BCA protein assay kit (Pierce). Oligonucleotides containing the AP-1 consensus sequence (5 0 -CGCTTGATGAGTCAGCCGGAA-3 0 ) were purchased from Promega. The end-labeled AP-1 oligonucleotides were made with [g-32 P]ATP (6000 Ci/nmol; Amersham) using T4 polynucleotide kinase. DNA-protein interactions for EMSA were carried out in volumes of 10 ml containing 3-5 mg of RT101 nuclear extracts, 2 ml of binding buffer (20% glycerol, 5 mm MgCl 2 , 2.5 mm EDTA, 2.5 mm DTT, 250 mm NaCl, 50 mm Tris-HCl (pH 7.5), and 0.25 mg/ ml poly(dI-dC) Á poly(dC-dI)), and 1 ml (30 000-50 000 c.p.m.) of labeled AP-1 oligonucleotide. After incubation of this reaction mixture at room temperature for 20 min, c-Fos, c-Jun, Fra-1, or JunD antibody (Santa Cruz Biotechnology) was added and incubated for an additional 20 min. The products of the binding reaction were resolved on 6% polyacrylamide nondenaturing gels in 0.5 Â TBE buffer.
